Select Publications

Journal articles

Heyer EE; Deveson IW; Wooi D; Selinger CI; Lyons RJ; Hayes VM; O’Toole SA; Ballinger ML; Gill D; Thomas DM; Mercer TR; Blackburn J, 2020, 'Author Correction: Diagnosis of fusion genes using targeted RNA sequencing (Nature Communications, (2019), 10, 1, (1388), 10.1038/s41467-019-09374-9)', Nature Communications, vol. 11,

Bartley N; Best M; Jacobs C; Juraskova I; Newson AJ; Savard J; Meiser B; Ballinger ML; Thomas DM; Biesecker B; Butow P, 2020, 'Cancer patients' views and understanding of genome sequencing: A qualitative study', Journal of Medical Genetics, vol. 57, pp. 671 - 676,

Davies G; Butow P; Napier CE; Bartley N; Juraskova I; Meiser B; Ballinger ML; Thomas DM; Schlub TE; Best MC, 2020, 'Advanced Cancer Patient Knowledge of and Attitudes towards Tumor Molecular Profiling', Translational Oncology, vol. 13, pp. 100799,

Butow P; Davies G; Napier CE; Schlub T; Best MC; Bartley N; Juraskova I; Meiser B; Ballinger ML; Biesecker B; Goldstein D; Thomas DM, 2020, 'Assessment of the Value of Tumor Variation Profiling Perceived by Patients With Cancer', JAMA network open, vol. 3, pp. e204721,

Mirabello L; Zhu B; Koster R; Karlins E; Dean M; Yeager M; Gianferante M; Spector LG; Morton LM; Karyadi D; Robison LL; Armstrong GT; Bhatia S; Song L; Pankratz N; Pinheiro M; Gastier-Foster JM; Gorlick R; De Toledo SRC; Petrilli AS; Patino-Garcia A; Lecanda F; Gutierrez-Jimeno M; Serra M; Hattinger C; Picci P; Scotlandi K; Flanagan AM; Tirabosco R; Amary MF; Kurucu N; Ilhan IE; Ballinger ML; Thomas DM; Barkauskas DA; Mejia-Baltodano G; Valverde P; Hicks BD; Wang M; Hutchinson AA; Tucker M; Sampson J; Landi MT; Freedman ND; Gapstur S; Carter B; Hoover RN; Chanock SJ; Savage SA, 2020, 'Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients with Osteosarcoma', JAMA Oncology, vol. 6, pp. 724 - 734,

Best MC; Butow P; Jacobs C; Savard J; Biesecker B; Ballinger ML; Bartley N; Davies G; Napier CE; Smit AK; Thomas DM; Newson AJ, 2020, 'Who should access germline genome sequencing? A mixed methods study of patient views', Clinical Genetics, vol. 97, pp. 329 - 337,

Shin SJ; Dodd-Eaton EB; Peng G; Bojadzieva J; Chen J; Amos CI; Frone MN; Khincha PP; Mai PL; Savage SA; Ballinger ML; Thomas DM; Yuan Y; Strong LC; Wang W, 2020, 'Penetrance of different cancer types in families with Li-Fraumeni syndrome: A validation study using multicenter cohorts', Cancer Research, vol. 80, pp. 354 - 360,

Smit AK; Bartley N; Best MC; Napier CE; Butow P; Newson AJ; Tucker K; Ballinger ML; Thomas DM; Jacobs C; Meiser B; Goldstein D; Savard J; Juraskova I, 2020, 'Family communication about genomic sequencing: A qualitative study with cancer patients and relatives', Patient Education and Counseling,

Kovac M; Woolley C; Ribi S; Blattmann C; Roth E; Morini M; Kovacova M; Ameline B; Kulozik A; Bielack S; Hartmann W; Ballinger ML; Thomas DM; Tomlinson I; Nathrath M; Heinimann K; Baumhoer D, 2020, 'Germline RET variants underlie a subset of paediatric osteosarcoma', Journal of Medical Genetics,

Heyer EE; Deveson IW; Wooi D; Selinger CI; Lyons RJ; Hayes VM; O’Toole SA; Ballinger ML; Gill D; Thomas DM; Mercer TR; Blackburn J, 2019, 'Diagnosis of fusion genes using targeted RNA sequencing', Nature Communications, vol. 10,

Best MC; Bartley N; Jacobs C; Juraskova I; Goldstein D; Newson AJ; Savard J; Meiser B; Ballinger M; Napier C; Thomas D; Biesecker B; Butow P; Tucker K; Schlub T; Vines R; Vines K; Kirk J; Young MA, 2019, 'Patient perspectives on molecular tumor profiling: "why wouldn't you?"', BMC Cancer, vol. 19, pp. 753,

Fortuno C; Cipponi A; Ballinger ML; Tavtigian SV; Olivier M; Ruparel V; Haupt Y; Haupt S; Study ISK; Tucker K; Spurdle AB; Thomas DM; James PA, 2019, 'A quantitative model to predict pathogenicity of missense variants in the TP53 gene', Human Mutation, vol. 40, pp. 788 - 800,

Thavaneswaran S; Rath E; Tucker K; Joshua AM; Hess D; Pinese M; Ballinger ML; Thomas DM, 2019, 'Author Correction: Therapeutic implications of germline genetic findings in cancer (Nature Reviews Clinical Oncology, (2019), 16, 6, (386-396), 10.1038/s41571-019-0179-3)', Nature Reviews Clinical Oncology, vol. 16, pp. 397,

Thavaneswaran S; Rath E; Tucker K; Joshua AM; Hess D; Pinese M; Ballinger ML; Thomas DM, 2019, 'Therapeutic implications of germline genetic findings in cancer', Nature Reviews Clinical Oncology, vol. 16, pp. 386 - 396,

Jones RM; Melton PE; Pinese M; Rea AJ; Ingley E; Ballinger ML; Wood DJ; Thomas DM; Moses EK, 2019, 'Identification of novel sarcoma risk genes using a two-stage genome wide DNA sequencing strategy in cancer cluster families and population case and control cohorts', BMC Medical Genetics, vol. 20,

Thavaneswaran S; Sebastian L; Ballinger M; Best M; Hess D; Lee CK; Sjoquist KM; Hague WE; Butow PN; Simes RJ; Thomas D, 2018, 'Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal-seeking studies of targeted therapies for rare and neglected cancers', The Medical journal of Australia, vol. 209, pp. 354 - 355,

Willis AM; Smith SK; Meiser B; Ballinger ML; Thomas DM; Tattersall M; Young MA, 2018, 'Development and Pilot Testing of a Decision Aid for Genomic Research Participants Notified of Clinically Actionable Research Findings for Cancer Risk', Journal of Genetic Counseling, vol. 27, pp. 1055 - 1066,

Best M; Newson AJ; Meiser B; Juraskova I; Goldstein D; Tucker K; Ballinger ML; Hess D; Schlub TE; Biesecker B; Vines R; Vines K; Thomas D; Young MA; Savard J; Jacobs C; Butow P, 2018, 'The PiGeOn project: Protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer', BMC Cancer, vol. 18,

Koster R; Panagiotou OA; Wheeler WA; Karlins E; Gastier-Foster JM; Caminada de Toledo SR; Petrilli AS; Flanagan AM; Tirabosco R; Andrulis IL; Wunder JS; Gokgoz N; Patiño-Garcia A; Lecanda F; Serra M; Hattinger C; Picci P; Scotlandi K; Thomas DM; Ballinger ML; Gorlick R; Barkauskas DA; Spector LG; Tucker M; Belynda DH; Yeager M; Hoover RN; Wacholder S; Chanock SJ; Savage SA; Mirabello L, 2018, 'Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients', International Journal of Cancer, vol. 142, pp. 1594 - 1601,

Rasmussen V; Forrest LE; Rogasik M; Girodet M; Meeus P; Sunyach MP; Blay JY; Bally O; Brahmi M; Ballinger ML; Niedermayr E; Thomas DM; Halliday J; James P; Ray-Coquard I; Young MA, 2018, 'A comparison of Australian and French families affected by sarcoma: Perceptions of genetics and incidental findings', Personalized Medicine, vol. 15, pp. 13 - 24,

Ballinger ML; Best A; Mai PL; Khincha PP; Loud JT; Peters JA; Achatz MI; Chojniak R; Balieiro da Costa A; Santiago KM; Garber J; O'Neill AF; Eeles RA; Evans DG; Bleiker E; Sonke GS; Ruijs M; Loo C; Schiffman J; Naumer A; Kohlmann W; Strong LC; Bojadzieva J; Malkin D; Rednam SP; Stoffel EM; Koeppe E; Weitzel JN; Slavin TP; Nehoray B; Robson M; Walsh M; Manelli L; Villani A; Thomas DM; Savage SA, 2017, 'Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis', JAMA oncology, vol. 3, pp. 1634 - 1639,

Ballinger ML; Ferris NJ; Moodie K; Mitchell G; Shanley S; James PA; Thomas DM, 2017, 'Surveillance in Germline TP53 Mutation Carriers Utilizing Whole-Body Magnetic Resonance Imaging', JAMA oncology, vol. 3, pp. 1735 - 1736,

Willis AM; Smith SK; Meiser B; Ballinger ML; Thomas DM; Young MA, 2017, 'Sociodemographic, psychosocial and clinical factors associated with uptake of genetic counselling for hereditary cancer: a systematic review', Clinical Genetics, vol. 92, pp. 121 - 133,

McBride KA; Ballinger ML; Schlub TE; Young MA; Tattersall MHN; Kirk J; Eeles R; Killick E; Walker LG; Shanley S; Thomas DM; Mitchell G, 2017, 'Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?', Familial Cancer, vol. 16, pp. 423 - 432,

Peng G; Bojadzieva J; Ballinger ML; Li J; Blackford AL; Mai PL; Savage SA; Thomas DM; Strong LC; Wang W, 2017, 'Estimating TP53 mutation carrier probability in families with li-fraumeni syndrome using LFSPRO', Cancer Epidemiology Biomarkers and Prevention, vol. 26, pp. 837 - 844,

Leroy B; Ballinger ML; Baran-Marszak F; Bond GL; Braithwaite A; Concin N; Donehower LA; El-Deiry WS; Fenaux P; Gaidano G; Langerød A; Hellstrom-Lindberg E; Iggo R; Lehmann-Che J; Mai PL; Malkin D; Moll UM; Myers JN; Nichols KE; Pospisilova S; Ashton-Prolla P; Rossi D; Savage SA; Strong LC; Tonin PN; Zeillinger R; Zenz T; Fraumeni JF; Taschner PEM; Hainaut P; Soussi T, 2017, 'Recommended guidelines for validation, quality control, and reporting of TP53 variants in clinical practice', Cancer Research, vol. 77, pp. 1250 - 1260,

Ballinger ML; Thomas DM, 2016, 'Sarcoma and germ-line DICER1 mutations – Authors’ reply', The Lancet Oncology, vol. 17, pp. e471,

Ballinger ML; Goode DL; Ray-Coquard I; James PA; Mitchell G; Niedermayr E; Puri A; Schiffman JD; Dite GS; Cipponi A; Maki RG; Brohl AS; Myklebost O; Stratford EW; Lorenz S; Ahn SM; Ahn JH; Kim JE; Shanley S; Beshay V; Randall RL; Judson I; Seddon B; Campbell IG; Young MA; Sarin R; Blay JY; O'Donoghue SI; Thomas DM, 2016, 'Monogenic and polygenic determinants of sarcoma risk: an international genetic study', The Lancet Oncology, vol. 17, pp. 1261 - 1271,

Thomas DM; Ballinger ML, 2016, 'Diagnosis and management of hereditary sarcoma', Recent Results in Cancer Research, vol. 205, pp. 169 - 189,

McBride KA; Hallowell N; Tattersall MHN; Kirk J; Ballinger ML; Thomas DM; Mitchell G; Young MA, 2016, 'Timing and context: important considerations in the return of genetic results to research participants', Journal of Community Genetics, vol. 7, pp. 11 - 20,

Thomas D, 2016, 'International survey of awareness of genetic risk in the clinical sarcoma community', Asia Pac J Clin Oncol, vol. 12, pp. 133 - 142,

Mirabello L; Koster R; Moriarity BS; Spector LG; Meltzer PS; Gary J; Machiela MJ; Pankratz N; Panagiotou OA; Largaespada D; Wang Z; Gastier-Foster JM; Gorlick R; Khanna C; de Toledo SRC; Petrilli AS; Patiño-Garcia A; Sierrasesúmaga L; Lecanda F; Andrulis IL; Wunder JS; Gokgoz N; Serra M; Hattinger C; Picci P; Scotlandi K; Flanagan AM; Tirabosco R; Amary MF; Halai D; Ballinger ML; Thomas DM; Davis S; Barkauskas DA; Marina N; Helman L; Otto GM; Becklin KL; Wolf NK; Weg MT; Tucker M; Wacholder S; Fraumeni JF; Caporaso NE; Boland JF; Hicks BD; Vogt A; Burdett L; Yeager M; Hoover RN; Chanock SJ; Savage SA, 2015, 'A genome-wide scan identifies variants in NFIB associated with metastasis in patients with osteosarcoma', Cancer Discovery, vol. 5, pp. 920 - 931,

Ballinger ML; Mitchell G; Thomas DM, 2015, 'Surveillance recommendations for patients with germline TP53 mutations', Current Opinion in Oncology, vol. 27, pp. 332 - 337,

Thomas DM; James PA; Ballinger ML, 2015, 'Clinical implications of genomics for cancer risk genetics', The Lancet Oncology, vol. 16, pp. e303 - e308,

Thomas DM; Ballinger ML, 2015, 'Etiologic, environmental and inherited risk factors in sarcomas', Journal of Surgical Oncology, vol. 111, pp. 490 - 495,

McBride KA; Ballinger ML; Killick E; Kirk J; Tattersall MHN; Eeles RA; Thomas DM; Mitchell G, 2014, 'Li-Fraumeni syndrome: Cancer risk assessment and clinical management', Nature Reviews Clinical Oncology, vol. 11, pp. 260 - 271,

Mitchell G; Ballinger ML; Wong S; Hewitt C; James P; Young MA; Cipponi A; Pang T; Goode DL; Dobrovic A; Thomas DM; Porceddu S; Gattas M; Neuhaus S; Suthers G; Tattersall M; Tucker K; Lewis C; Carey-Smith R, 2013, 'High Frequency of Germline TP53 Mutations in a Prospective Adult-Onset Sarcoma Cohort', PLoS ONE, vol. 8,

Little PJ; Rostam MA; Piva TJ; Getachew R; Kamato D; Guidone D; Ballinger ML; Zheng W; Osman N, 2013, 'Suramin inhibits PDGF-stimulated receptor phosphorylation, proteoglycan synthesis and glycosaminoglycan hyperelongation in human vascular smooth muscle cells', Journal of Pharmacy and Pharmacology, vol. 65, pp. 1055 - 1063,

Osman N; Grande-Allen KJ; Ballinger ML; Getachew R; Marasco S; O'Brien KD; Little PJ, 2013, 'Smad2-dependent glycosaminoglycan elongation in aortic valve interstitial cells enhances binding of LDL to proteoglycans', Cardiovascular Pathology, vol. 22, pp. 146 - 155,

Young M-A; Herlihy A; Mitchell G; Thomas DM; Ballinger M; Tucker K; Lewis CR; Neuhaus S; Halliday J, 2013, 'The attitudes of people with sarcoma and their family towards genomics and incidental information arising from genetic research', Clinical Sarcoma Research, vol. 3, pp. 11 - 11,

Downing ME; Dite GS; Ballinger ML, 2012, 'An increased incidence of Hodgkin's lymphoma in patients with adult-onset sarcoma', CLINICAL SARCOMA RESEARCH, vol. 2,

Little PJ; Getachew R; Rezaei HB; Sanchez-Guerrero E; Khachigian LM; Wang H; Liao S; Zheng W; Ballinger ML; Osman N, 2012, 'Genistein inhibits PDGF-stimulated proteoglycan synthesis in vascular smooth muscle without blocking PDGFâ receptor phosphorylation', Archives of Biochemistry and Biophysics, vol. 525, pp. 25 - 31,

Thomas DM; Ballinger ML, 2012, 'Inherited and germline TP53 mutations in adult-onset sarcoma.', Hereditary cancer in clinical practice, vol. 10, pp. A3 - A3,

Thomas DM; Ballinger ML, 2012, 'Inherited and germline TP53 mutations in adult-onset sarcoma.', Hereditary cancer in clinical practice, vol. 10, pp. A26 - A26,

Mahendran K; Ballinger M; Kirk J; Thomas D; Tattersall M, 2012, 'Pathogenic germline TP53 mutations in adult sarcoma patients; implications for treatment and screening – description of an upcoming project.', Hereditary cancer in clinical practice, vol. 10, pp. A61 - A61,

Burch ML; Ballinger ML; Yang SNY; Getachew R; Itman C; Loveland K; Osman N; Little PJ, 2010, 'Thrombin stimulation of proteoglycan synthesis in vascular smooth muscle is mediated by protease-activated receptor-1 transactivation of the transforming growth factor βtype I receptor', Journal of Biological Chemistry, vol. 285, pp. 26798 - 26805,

Ballinger ML; Osman N; Hashimura K; Haan JBD; Jandeleit-Dahm K; Allen T; Tannock LR; Rutledge JC; Little PJ, 2010, 'Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo', Journal of Cellular and Molecular Medicine, vol. 14, pp. 1408 - 1418,

Burch ML; Yang SNY; Ballinger ML; Getachew R; Osman N; Little PJ, 2010, 'TGF-β stimulates biglycan synthesis via p38 and ERK phosphorylation of the linker region of Smad2', Cellular and Molecular Life Sciences, vol. 67, pp. 2077 - 2090,

Cardoso LEM; Little PJ; Ballinger ML; Chan CK; Braun KR; Potter-Perigo S; Bornfeldt KE; Kinsella MG; Wight TN, 2010, 'Platelet-derived growth factor differentially regulates the expression and post-translational modification of versican by arterial smooth muscle cells through distinct protein kinase C and extracellular signal-regulated kinase pathways', Journal of Biological Chemistry, vol. 285, pp. 6987 - 6995,

Getachew R; Ballinger ML; Burch ML; Little PJ; Osman N, 2010, 'Characterisation of Ki11502 as a potent inhibitor of PDGF β receptor-mediated proteoglycan synthesis in vascular smooth muscle cells', European Journal of Pharmacology, vol. 626, pp. 186 - 192,

Back to profile page